Author
Listed:
- Sebastian Braun
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Paulina Bolivar
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Clara Oudenaarden
(University of Copenhagen, Biotech Research and Innovation Centre)
- Jonas Sjölund
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Matteo Bocci
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Katja Harbst
(Lund University, Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University Cancer Centre)
- Mehrnaz Safaee Talkhoncheh
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Bengt Phung
(Lund University, Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University Cancer Centre)
- Eugenia Cordero
(Lund University, Department of Clinical Sciences, Malmö, Lund University Diabetes Centre)
- Rebecca Rosberg
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Elinn Johansson
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Göran B. Jönsson
(Lund University, Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University Cancer Centre)
- Alexander Pietras
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre)
- Kristian Pietras
(Lund University, Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre
Lund University, SciLifeLab, Department of Laboratory Medicine)
Abstract
Glioblastoma (GBM) is characterized by fast progression, infiltrative growth pattern, and a high relapse rate. A defining feature of GBM is the existence of spatially and functionally distinct cellular niches, where malignant cells engage in paracrine crosstalk with cell types comprising the tumor microenvironment. Here, we identify pericytes as the most active paracrine signaling hub within the tumor parenchyma. Their depletion through genetic engineering results in accelerated tumor progression and shortened survival. Mechanistic studies reveal that pericyte deficiency remodels the endothelium and impacts the immune cell landscape, exacerbating tumor cell invasion and immune suppression. Specifically, the pericyte-deprived endothelium recruits perivascular, tumor-associated macrophages polarized towards an immune-suppressive phenotype. The recruited macrophages express Hepatocyte Growth Factor, which reinforces activation of its receptor tyrosine kinase MET on GBM cells harboring a pronounced mesenchymal subtype driven by the key phenotypic regulator Fosl1. Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy.
Suggested Citation
Sebastian Braun & Paulina Bolivar & Clara Oudenaarden & Jonas Sjölund & Matteo Bocci & Katja Harbst & Mehrnaz Safaee Talkhoncheh & Bengt Phung & Eugenia Cordero & Rebecca Rosberg & Elinn Johansson & G, 2025.
"Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma,"
Nature Communications, Nature, vol. 16(1), pages 1-22, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-66985-1
DOI: 10.1038/s41467-025-66985-1
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-66985-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.